IL145514A0 - Akt nucleic acids, polypeptides, and uses thereof - Google Patents

Akt nucleic acids, polypeptides, and uses thereof

Info

Publication number
IL145514A0
IL145514A0 IL14551400A IL14551400A IL145514A0 IL 145514 A0 IL145514 A0 IL 145514A0 IL 14551400 A IL14551400 A IL 14551400A IL 14551400 A IL14551400 A IL 14551400A IL 145514 A0 IL145514 A0 IL 145514A0
Authority
IL
Israel
Prior art keywords
polypeptides
nucleic acids
akt3
akt nucleic
relates
Prior art date
Application number
IL14551400A
Other languages
English (en)
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of IL145514A0 publication Critical patent/IL145514A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
IL14551400A 1999-03-19 2000-03-14 Akt nucleic acids, polypeptides, and uses thereof IL145514A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12510899P 1999-03-19 1999-03-19
PCT/US2000/006574 WO2000056866A2 (en) 1999-03-19 2000-03-14 Akt-3 nucleic acids, polypeptides, and uses thereof

Publications (1)

Publication Number Publication Date
IL145514A0 true IL145514A0 (en) 2002-06-30

Family

ID=22418217

Family Applications (4)

Application Number Title Priority Date Filing Date
IL14198400A IL141984A0 (en) 1999-03-19 2000-03-14 Akt nucleic acids, polypeptides, and uses thereof
IL14551400A IL145514A0 (en) 1999-03-19 2000-03-14 Akt nucleic acids, polypeptides, and uses thereof
IL145514A IL145514A (en) 1999-03-19 2001-09-20 Akt nucleic acids, vectors, host cells, antibodies, recombinant viruses, methods and pharmaceutical compositions thereof
IL190270A IL190270A (en) 1999-03-19 2008-03-18 Use of 3AKT nucleic acids for the preparation of a drug for the treatment of cell death, treatment of myocardial infarction or injury due to blockage in the blood supply

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL14198400A IL141984A0 (en) 1999-03-19 2000-03-14 Akt nucleic acids, polypeptides, and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL145514A IL145514A (en) 1999-03-19 2001-09-20 Akt nucleic acids, vectors, host cells, antibodies, recombinant viruses, methods and pharmaceutical compositions thereof
IL190270A IL190270A (en) 1999-03-19 2008-03-18 Use of 3AKT nucleic acids for the preparation of a drug for the treatment of cell death, treatment of myocardial infarction or injury due to blockage in the blood supply

Country Status (18)

Country Link
EP (1) EP1144600B1 (de)
JP (1) JP4237945B2 (de)
KR (1) KR100700908B1 (de)
AT (1) ATE402995T1 (de)
AU (1) AU782448B2 (de)
BR (1) BR0009170A (de)
CA (1) CA2343074C (de)
CY (1) CY1108459T1 (de)
DE (1) DE60039677D1 (de)
DK (1) DK1144600T3 (de)
ES (1) ES2310515T3 (de)
HK (1) HK1041288B (de)
IL (4) IL141984A0 (de)
NO (1) NO20014537L (de)
PT (1) PT1144600E (de)
SI (1) SI1144600T1 (de)
WO (1) WO2000056866A2 (de)
ZA (1) ZA200108414B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
NZ514305A (en) 1999-04-16 2004-01-30 Univ Yale eNOS mutations useful for gene therapy and therapeutic screening
JP2003530818A (ja) * 1999-06-11 2003-10-21 アベンティス・ファーマスーティカルズ・インコーポレイテツド セリン／トレオニンプロテインキナーゼＡｋｔによる血管内皮成長因子（ＶＥＧＦ）の導入
WO2003063905A1 (fr) * 2002-01-31 2003-08-07 Center For Advanced Science And Technology Incubation, Ltd. Medicaments preventifs ou remedes pour maladies immunologiques
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
WO2005009470A1 (ja) * 2003-07-28 2005-02-03 Osaka Industrial Promotion Organization Ａｓｋ１阻害剤を有効成分とする心不全治療薬およびそのスクリーニング方法
WO2009148896A2 (en) 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
MX2012015105A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Inhibidores de cinasa de regulacion mediante señal de apoptosis.
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CA2962572A1 (en) 2014-09-24 2016-03-31 Gilead Sciences, Inc. Methods of treating liver disease with a combination of an ask1 inhibitor and a fxr agonist
EP3693366B8 (de) 2014-12-23 2023-08-09 Gilead Sciences, Inc. Verfahren zur herstellung von ask1-inhibitoren
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109197A (ja) * 1994-10-07 1996-04-30 Sumitomo Electric Ind Ltd 白血病腫瘍拒絶抗原ペプチド
DK0862622T3 (da) * 1995-11-16 2004-12-20 Novartis Ag Fremgangsmåde til identifikation af forbindelser, der vekselvirker med RAC-proteinkinase
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3
US6043090A (en) * 1999-03-23 2000-03-28 Isis Pharmaceuticals Inc. Antisense inhibition of human Akt-2 expression
AU3774500A (en) * 1999-03-31 2000-10-16 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; "orfx"
JP2003530818A (ja) * 1999-06-11 2003-10-21 アベンティス・ファーマスーティカルズ・インコーポレイテツド セリン／トレオニンプロテインキナーゼＡｋｔによる血管内皮成長因子（ＶＥＧＦ）の導入

Also Published As

Publication number Publication date
WO2000056866A2 (en) 2000-09-28
WO2000056866A9 (en) 2002-08-29
ZA200108414B (en) 2003-03-26
JP4237945B2 (ja) 2009-03-11
IL190270A (en) 2012-12-31
KR100700908B1 (ko) 2007-03-29
DK1144600T3 (da) 2008-11-24
EP1144600B1 (de) 2008-07-30
IL141984A0 (en) 2002-03-10
CA2343074A1 (en) 2000-09-28
EP1144600A2 (de) 2001-10-17
NO20014537L (no) 2001-10-31
IL145514A (en) 2010-05-17
SI1144600T1 (sl) 2008-12-31
WO2000056866A3 (en) 2001-02-15
ATE402995T1 (de) 2008-08-15
ES2310515T3 (es) 2009-01-16
CA2343074C (en) 2010-09-21
DE60039677D1 (de) 2008-09-11
AU3880200A (en) 2000-10-09
AU782448B2 (en) 2005-07-28
JP2002539781A (ja) 2002-11-26
NO20014537D0 (no) 2001-09-18
BR0009170A (pt) 2002-04-30
PT1144600E (pt) 2008-10-10
KR20020011972A (ko) 2002-02-09
HK1041288B (zh) 2008-11-07
CY1108459T1 (el) 2013-09-04
HK1041288A1 (en) 2002-07-05

Similar Documents

Publication Publication Date Title
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
WO2003103589A3 (en) USE OF IL-21 IN THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS
WO2000055345A3 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
MX344216B (es) Productos geneticos expresados de forma diferencial en tumores y su uso.
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
PL308122A1 (en) Viral vectors and their application in genic therapy
EP1319023B8 (de) Peptid aus hsp70 welches nk zellaktivität stimuliert und seine verwendung
WO2001034641A8 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
GB0418388D0 (en) Cell therapy
MXPA04001720A (es) Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
AU2002304249A1 (en) Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
NZ516237A (en) Meth1 and meth2 polynucleotides and polypeptides
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
UA84831C2 (ru) Производные фактора коагуляции vii
WO2001077338A3 (en) Human protein kinases and protein kinase-like enzymes
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
AU2002246455A1 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
HUP0300813A2 (hu) Gének, fehérjék és alkalmazásuk
DE60034874D1 (de) Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung
PL370854A1 (en) Ee3-protein family and corresponding dna sequences